Article
Multidisciplinary Sciences
Young-Jun Park, Dora Pinto, Alexandra C. Walls, Zhuoming Liu, Anna De Marco, Fabio Benigni, Fabrizia Zatta, Chiara Silacci-Fregni, Jessica Bassi, Kaitlin R. Sprouse, Amin Addetia, John E. Bowen, Cameron Stewart, Martina Giurdanella, Christian Saliba, Barbara Guarino, Michael A. Schmid, Nicholas M. Franko, Jennifer K. Logue, Ha V. Dang, Kevin Hauser, Julia di Iulio, William Rivera, Gretja Schnell, Anushka Rajesh, Jiayi Zhou, Nisar Farhat, Hannah Kaiser, Martin Montiel-Ruiz, Julia Noack, Florian A. Lempp, Javier Janer, Rana Abdelnabi, Piet Maes, Paolo Ferrari, Alessandro Ceschi, Olivier Giannini, Guilherme Dias De Melo, Lauriane Kergoat, Herve Bourhy, Johan Neyts, Leah Soriaga, Lisa A. Purcell, Gyorgy Snell, Sean P. J. Whelan, Antonio Lanzavecchia, Herbert W. Virgin, Luca Piccoli, Helen Y. Chu, Matteo Samuele Pizzuto, Davide Corti, David Veesler
Summary: SARS-CoV-2 Omicron sublineages have spike mutations that allow them to evade antibodies from previous infection or vaccination. Hybrid immunity or booster shots can generate neutralizing antibodies against Omicron variants, and breakthrough infections lead to the production of neutralizing antibodies in the nasal mucosa. Antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases show cross-reactivity with different receptor-binding domains, while primary Omicron infections elicit B cells with narrow specificity. A highly potent pan-variant-neutralizing antibody has been identified as a potential candidate for clinical development.
Article
Immunology
Shohei Yamamoto, Kenji Maeda, Kouki Matsuda, Akihito Tanaka, Kumi Horii, Kaori Okudera, Junko S. Takeuchi, Tetsuya Mizoue, Maki Konishi, Mitsuru Ozeki, Haruhito Sugiyama, Nobuyoshi Aoyanagi, Hiroaki Mitsuya, Wataru Sugiura, Norio Ohmagari
Summary: A study conducted among healthcare workers in a hospital in Tokyo during the Delta variant epidemic showed that breakthrough infections occurred 2-4 months after vaccination, with all cases being mild or asymptomatic. Despite lower neutralizing antibody titers against the variants compared to the wild-type, there was no difference in antibody levels between breakthrough cases and controls.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Cell Biology
Xilin Wu, Lin Cheng, Ming Fu, Bilian Huang, Linjing Zhu, Shijie Xu, Haixia Shi, Doudou Zhang, Huanyun Yuan, Waqas Nawaz, Ping Yang, Qinxue Hu, Yalan Liu, Zhiwei Wu
Summary: Neutralizing nanobodies derived from an alpaca immunized with SARS-CoV-2 spike glycoprotein show potential therapeutic effects against COVID-19. A trimer of Nbs, Nb-15-NbH-Nb-15, exhibits high neutralization potency against SARS-CoV-2 live virus and variants with a long half-life. Intranasal administration of Nb-15-Nb-H-Nb-15 provides effective protection against SARS-CoV-2 infection in transgenic hACE2 mice for both prophylactic and therapeutic purposes.
Article
Multidisciplinary Sciences
Jun Liu, Patrick Budylowski, Reuben Samson, Bryan D. Griffin, Giorgi Babuadze, Bhavisha Rathod, Karen Colwill, Jumai A. Abioye, Jordan A. Schwartz, Ryan Law, Lily Yip, Sang Kyun Ahn, Serena Chau, Maedeh Naghibosadat, Yuko Arita, Queenie Hu, Feng Yun Yue, Arinjay Banerjee, W. Rod Hardy, Karen Mossman, Samira Mubareka, Robert A. Kozak, Michael S. Pollanen, Natalia Martin Orozco, Anne-Claude Gingras, Eric G. Marcusson, Mario A. Ostrowski
Summary: This article reports the preclinical development of a lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. It was chosen among three candidates after showing the strongest immune response in mouse vaccination. Further tests in mice and hamsters demonstrated that PTX-COVID19-B induced robust immune responses and provided complete protection against SARS-CoV-2 infection.
Article
Multidisciplinary Sciences
Prabhu S. Arunachalam, Alexandra C. Walls, Nadia Golden, Caroline Atyeo, Stephanie Fischinger, Chunfeng Li, Pyone Aye, Mary Jane Navarro, Lilin Lai, Venkata Viswanadh Edara, Katharina Roltgen, Kenneth Rogers, Lisa Shirreff, Douglas E. Ferrell, Samuel Wrenn, Deleah Pettie, John C. Kraft, Marcos C. Miranda, Elizabeth Kepl, Claire Sydeman, Natalie Brunette, Michael Murphy, Brooke Fiala, Lauren Carter, Alexander G. White, Meera Trisal, Ching-Lin Hsieh, Kasi Russell-Lodrigue, Christopher Monjure, Jason Dufour, Skye Spencer, Lara Doyle-Meyers, Rudolph P. Bohm, Nicholas J. Maness, Chad Roy, Jessica A. Plante, Kenneth S. Plante, Alex Zhu, Matthew J. Gorman, Sally Shin, Xiaoying Shen, Jane Fontenot, Shakti Gupta, Derek T. O'Hagan, Robbert Van Der Most, Rino Rappuoli, Robert L. Coffman, David Novack, Jason S. McLellan, Shankar Subramaniam, David Montefiori, Scott D. Boyd, JoAnne L. Flynn, Galit Alter, Francois Villinger, Harry Kleanthous, Jay Rappaport, Mehul S. Suthar, Neil P. King, David Veesler, Bali Pulendran
Summary: This study demonstrated the effectiveness of an adjuvanted RBD-NP vaccine in inducing robust and durable neutralizing antibody responses, providing protection against SARS-CoV-2 infection, and cross-neutralizing various variants. Adjuvants such as AS03 and AS37 significantly enhanced the immunogenicity of the vaccine and have the potential to be candidates for COVID-19 vaccines.
Article
Immunology
Yu-An Kung, Sheng-Yu Huang, Chung-Guei Huang, Kuan-Ting Liu, Peng-Nien Huang, Kar-Yee Yu, Shu-Li Yang, Chia-Pei Chen, Ching-Yun Cheng, Ing-Kit Lee, Shu-Min Lin, Han-Pin Chang, Yueh-Te Lin, Yen-Chin Liu, Guang-Wu Chen, Shin-Ru Shih
Summary: The importance of an international standard for SARS-CoV-2 neutralizing antibody titer detection has been highlighted by the World Health Organization. In this study, we calibrated neutralizing antibody titers in response to COVID-19 vaccination using the international standard and analyzed the association between different factors and neutralizing antibodies. The findings have significant implications for vaccine development and the implementation of non-inferiority trials.
MICROBES AND INFECTION
(2023)
Article
Biochemistry & Molecular Biology
Maya Shofa, Tomotaka Okamura, Emiko Urano, Yoshiharu Matsuura, Yasuhiro Yasutomi, Akatsuki Saito
Summary: ZIKV outbreaks in Central and South America were finally controlled through various methods, including mosquito control and herd immunity. This study on cynomolgus monkeys showed that mucosal ZIKV infection can induce protective immunity without causing systemic viremia or symptoms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, Kumi Horii, Kaori Okudera, Yusuke Oshiro, Natsumi Inamura, Takashi Nemoto, Junko S. Takeuchi, Yunfei Li, Maki Konishi, Kiyoto Tsuchiya, Hiroyuki Gatanaga, Shinichi Oka, Tetsuya Mizoue, Haruhito Sugiyama, Nobuyoshi Aoyanagi, Hiroaki Mitsuya, Wataru Sugiura, Norio Ohmagari
Summary: Preinfection humoral immunity may protect against Omicron BA.5 infection, but it does not prevent long COVID. Preinfection neutralizing antibody titers against Omicron BA.5 approximately 6 months after the third vaccination are correlated with protection against Omicron BA.5 infection, but not against long COVID development.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Francesca Rovida, Irene Cassaniti, Elena Percivalle, Antonella Sarasini, Stefania Paolucci, Catherine Klersy, Sara Cutti, Viola Novelli, Carlo Marena, Francesco Luzzaro, Giovanni De Vito, Roberta Schiavo, Giuliana Lo Cascio, Daniele Lilleri, Fausto Baldanti
Summary: The study evaluated the protective effect of SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity induced by natural infection against SARS-CoV-2 infection. The results showed that immunity from natural infection can reduce the risk of secondary infection and alleviate symptoms.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Benjamin Trinite, Ferran Tarres-Freixas, Jordi Rodon, Edwards Pradenas, Victor Urrea, Silvia Marfl, Maria Luisa Rodriguez de la Concepcion, Carlos Avila-Nieto, Carmen Aguilar-Gurrieri, Ana Barajas, Raquel Ortiz, Roger Paredes, Lourdes Mateu, Alfonso Valencia, Victor Guallar, Lidia Ruiz, Eulalia Grau, Marta Massanella, Jordi Puig, Anna Chamorro, Nuria Izquierdo-Useros, Joaquim Segales, Bonaventura Clotet, Jorge Carrillo, Julia Vergara-Alert, Julia Blanco
Summary: The levels of neutralizing antibodies significantly increase with disease severity in COVID-19 patients. Hospitalized individuals have higher titers compared to those with mild symptoms or asymptomatic, with no significant impact from age, gender, or treatment on the neutralizing titers.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Tanyaporn Pongkunakorn, Thamonwan Manosan, Apinya Surawit, Suphawan Ophakas, Pichanun Mongkolsucharitkul, Sureeporn Pumeiam, Sophida Suta, Bonggochpass Pinsawas, Nitat Sookrung, Nawannaporn Saelim, Kodchakorn Mahasongkram, Pannathee Prangtaworn, Anchalee Tungtrongchitr, Watip Tangjittipokin, Suthee Mangmee, Kobporn Boonnak, Tassanee Narkdontri, Nipaporn Teerawattanapong, Rungsima Wanitphadeedecha, Korapat Mayurasakorn
Summary: During the Omicron pandemic, the immune response of individuals with post-COVID full recovery and long COVID (LC) was compared. The study found that LC patients had lower neutralizing antibody levels and reduced T cell subsets, indicating the need for earlier booster vaccinations to restore immune function in symptomatic LC individuals.
Article
Materials Science, Biomaterials
Izabela Stupka, Artur P. Biela, Bernard Piette, Agnieszka Kowalczyk, Karolina Majsterkiewicz, Kinga Borzecka-Solarz, Antonina Naskalska, Jonathan G. Heddle
Summary: Artificial protein cages, such as TRAP-cages, have potential applications in vaccines and drug delivery. TRAP-cages have the ability to control the disassembly conditions by modifying the interface between their building blocks. By using TRAP rings with different numbers of monomers, it is possible to predict the formation of other cages.
JOURNAL OF MATERIALS CHEMISTRY B
(2024)
Article
Immunology
Jing Li, Jingjing Li, Shuzhi Dai, Li Dang, Lin Wang, Ling Cao, Xiaobo Chen, Ying Wang, Menglei Ge, Weijie Liu, Qinwei Song, Wenjian Xu, Lijuan Ma
Summary: Objective analysis of SARS-CoV-2 IgG antibody and neutralizing antibody levels in children aged 3-11 years, comparing vaccinated and unvaccinated individuals, provides evidence for formulating vaccination strategies and control policies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Nesrin Gareayaghi, Mehmet Demirci, Dogukan Ozbey, Ferhat Dasdemir, Harika Oyku Dinc, Ilker Inanc Balkan, Suat Saribas, Nese Saltoglu, Bekir Kocazeybek
Summary: This study aimed to determine the levels of anti-S-RBD IgG antibodies and neutralizing antibody inhibition percentages (nAb IH%) formed after two doses of inactive or mRNA-based vaccine and a booster dose. The results showed that the heterologous booster dose led to a significant increase in both anti-S-RBD IgG levels and neutralizing antibodies. The study also found that the levels of binding and neutralizing antibodies were similar between those who received a heterologous booster dose and those who received a homologous booster dose, regardless of prior COVID-19 history.
Article
Pharmacology & Pharmacy
Guillaume Lingas, Delphine Planas, Helene Pere, Francoise Porrot, Florence Guivel-Benhassine, Isabelle Staropoli, Darragh Duffy, Nicolas Chapuis, Camille Gobeaux, David Veyer, Constance Delaugerre, Jerome Le Goff, Prunelle Getten, Jerome Hadjadj, Adele Bellino, Beatrice Parfait, Jean-Marc Treluyer, Olivier Schwartz, Jeremie Guedj, Solen Kerneis, Benjamin Terrier
Summary: This study analyzed the kinetics of neutralizing antibody levels during acute infection with the alpha variant and showed that increases in neutralizing antibodies led to a shorter half-life of infected cells and infectious viral particles, resulting in rapid viral clearance. Simulation studies predicted that a high neutralizing activity could significantly reduce the risk of detectable viral load and infectiousness.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Immunology
Sam X. Li, Bradley S. Barrett, Kejun Guo, Mario L. Santiago
CURRENT HIV RESEARCH
(2016)
Review
Biotechnology & Applied Microbiology
Yaqiong Wang, Kimberly Schmitt, Kejun Guo, Mario L. Santiago, Edward B. Stephens
JOURNAL OF GENERAL VIROLOGY
(2016)
Article
Virology
Kerry J. Lavender, Kathrin Gibbert, Karin E. Peterson, Erik Van Dis, Sandra Francois, Tyson Woods, Ronald J. Messer, Ali Gawanbacht, Janis A. Mueller, Jan Muench, Katie Phillips, Brent Race, Michael S. Harper, Kejun Guo, Eric J. Lee, Mirko Trilling, Hartmut Hengel, Jacob Piehler, Jens Verheyen, Cara C. Wilson, Mario L. Santiago, Kim J. Hasenkrug, Ulf Dittmer
JOURNAL OF VIROLOGY
(2016)
Article
Multidisciplinary Sciences
Kira Rubtsova, Anatoly V. Rubtsov, Kalani Halemano, Sam X. Li, John W. Kappler, Mario L. Santiago, Philippa Marrack
Article
Virology
Yaqiong Wang, Zekun Wang, Ankita Pramanik, Mario L. Santiago, Jianming Qiu, Edward B. Stephens
Article
Immunology
Andrew Getahun, Scott M. Wemlinger, Pratyaydipta Rudra, Mario L. Santiago, Linda F. van Dyk, John C. Cambier
JOURNAL OF EXPERIMENTAL MEDICINE
(2017)
Article
Immunology
Kristin M. S. Schroeder, Amanda Agazio, Pamela J. Strauch, Sean T. Jones, Scott B. Thompson, Michael S. Harper, Roberta Pelanda, Mario L. Santiago, Raul M. Torres
JOURNAL OF EXPERIMENTAL MEDICINE
(2017)
Article
Virology
Shannon M. Miller, Brodie Miles, Kejun Guo, Joy Folkvord, Amie L. Meditz, Martin D. McCarter, David N. Levy, Samantha MaWhinney, Mario L. Santiago, Elizabeth Connick
JOURNAL OF VIROLOGY
(2017)
Article
Virology
Bradley S. Barrett, Michael S. Harper, Sean T. Jones, Kejun Guo, Karl J. Heilman, Ross M. Kedl, Kim J. Hasenkrug, Mario L. Santiago
Article
Microbiology
Alyson C. Yoder, Kejun Guo, Stephanie M. Dillon, Tzu Phang, Eric J. Lee, Michael S. Harper, Karen Helm, John C. Kappes, Christina Ochsenbauer, Martin D. McCarter, Cara C. Wilson, Mario L. Santiago
Article
Virology
Joseph A. Westrich, Cody J. Warren, Michael J. Klausner, Kejun Guo, Chang-Wei Liu, Mario L. Santiago, Dohun Pyeon
JOURNAL OF VIROLOGY
(2018)
Article
Multidisciplinary Sciences
Sam X. Li, Bradley S. Barrett, Kejun Guo, George Kassiotis, Kim J. Hasenkrug, Ulf Dittmer, Kathrin Gibbert, Mario L. Santiago
SCIENTIFIC REPORTS
(2016)
Article
Multidisciplinary Sciences
Kejun Guo, Bradley S. Barrett, James H. Morrison, Kaylee L. Mickens, Eszter K. Vladar, Kim J. Hasenkrug, Eric M. Poeschla, Mario L. Santiago
Summary: The emergence of SARS-CoV-2 variants with enhanced resistance to interferons suggests that evasion of innate immunity may be a driving force in the evolution of the virus.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Immunology
Chelsea Iwamoto, Kelsey E. Lesteberg, Molly M. Lamb, Diva M. Calvimontes, Kejun Guo, Bradley S. Barrett, Kaylee L. Mickens, Lindsey M. Duca, Jose Monzon, Anna N. Chard, Gerber Guzman, Edgar Barrios, Neudy Rojop, Kareen Arias, Melissa Gomez, Claudia Paiz, Guillermo Antonio Bolanos, Kathryn M. Edwards, Emily Zielinski Gutierrez, Eduardo Azziz-Baumgartner, Edwin J. Asturias, Mario L. Santiago, J. David Beckham, Daniel Olson
Summary: Essential agricultural workers face increased risk of SARS-CoV-2 exposure and transmission. A cohort study in Guatemala found that coughing and working as a packer or packing manager were associated with higher risk of SARS-CoV-2 infection. Antibody titers decreased rapidly, highlighting the need for comprehensive prevention strategies, including vaccination, in the workplace.
Article
Immunology
Stephanie M. Dillon, Jon Kibbie, Eric J. Lee, Kejun Guo, Mario L. Santiago, Gregory L. Austin, Sara Gianella, Alan L. Landay, Andrew M. Donovan, Daniel N. Frank, Martin D. McCarter, Cara C. Wilson